ANTIANGINAL EFFECTS OF AMLODIPINE AT A SINGLE DOSE ON EXERTIONAL ANGINA PATIENTS USING TREADMILL EXERCISE TESTING - A RANDOMIZED CROSSOVER STUDY IN COMPARISON WITH PLACEBO

被引:3
作者
KISHIDA, H
HATA, N
KUNIMI, T
MIYAGAWA, H
NISHIYAMA, H
KATOH, K
机构
[1] NATL YOKOSUKA HOSP,DEPT CARDIOL,YOKOSUKA,JAPAN
[2] CARDIOVASC INST,TOKYO,JAPAN
关键词
EXERCISE TEST; ANTIANGINAL AGENT; CALCIUM ANTAGONIST; AMLODIPINE; PRESSURE-RATE PRODUCT;
D O I
10.1007/BF00055605
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With eight cases of stable exertional angina as subjects, the antianginal action and sustained effects of single 10 mg oral doses of new calcium antagonists amlodipine were assessed by treadmill exercise tests in randomized crossover trials with respect to a placebo. Exercise tests were conducted before as well as 4, 8, and 24 hours after administration, and plasma amlodipine concentration was investigated at the same times. The maximal exercise time was 299 +/- 43 seconds before as compared with 346 +/- 49 seconds 4 hours after administration and 368 +/- 50 seconds 8 hours after administration, a significant prolongation in each case (p < 0.01). Moreover, the exercise time elapsed until 1 mm of ST-segment depression, as well as the ST-segment depression measured at the same time, were both significantly improved as compared with the placebo results. The plasma amlodipine concentration reached a peak 8 hours after administration and displayed an effective level even 24 hours after administration. The value of DELTAPRP measured at the same time during the exercise test was also significantly reduced as compared with the placebo results, even 24 hours after administration of amlodipine. These findings supported the conclusion that single 10-mg doses of amlodipine provide stable antianginal action over a 24-hour period.
引用
收藏
页码:481 / 487
页数:7
相关论文
共 18 条
[1]  
ABERNETHY DR, 1988, J CARDIOVASC PHAR S7, V12, pS27
[2]  
BURGES RA, 1985, BRIT J PHARMACOL, V85, P281
[3]   EFFICACY AND SAFETY OF AMLODIPINE IN VASOSPASTIC ANGINA - AN INTERIM-REPORT OF A MULTICENTER, PLACEBO-CONTROLLED TRIAL [J].
CHAHINE, RA ;
FELDMAN, RL ;
GILES, TD ;
RAIZNER, AE ;
WEISS, RJ ;
NICOD, P .
AMERICAN HEART JOURNAL, 1989, 118 (05) :1128-1130
[4]   THE PHARMACOKINETICS OF AMLODIPINE IN HEALTHY-VOLUNTEERS AFTER SINGLE INTRAVENOUS AND ORAL DOSES AND AFTER 14 REPEATED ORAL DOSES GIVEN ONCE DAILY [J].
FAULKNER, JK ;
MCGIBNEY, D ;
CHASSEAUD, LF ;
PERRY, JL ;
TAYLOR, IW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) :21-25
[5]   PHARMACODYNAMICS OF AMLODIPINE - HEMODYNAMIC-EFFECTS AND ANTIANGINAL EFFICACY AFTER ATRIAL-PACING [J].
HOGG, KJ ;
HORNUNG, RS ;
HILLIS, WS ;
GUPTA, S ;
GRANT, P ;
SINGH, SP .
AMERICAN HEART JOURNAL, 1989, 118 (05) :1107-1113
[6]  
JACKSON NC, 1985, BR J CLIN PHARM, V20, P248
[7]   AMLODIPINE IN HYPERTENSION - AN OVERVIEW OF THE CLINICAL DOSSIER [J].
JULIUS, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S27-S33
[8]   ENDURANCE TESTING FOR EVALUATION OF ANTIANGINAL THERAPY WITH AMLODIPINE, A CALCIUM-CHANNEL BLOCKING-AGENT [J].
KINNARD, DR ;
HARRIS, M ;
HOSSACK, KF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (03) :791-796
[9]   ARTERIAL VASODILATOR EFFECTS OF THE DIHYDROPYRIDINE CALCIUM-ANTAGONIST AMLODIPINE ALONE AND IN COMBINATION WITH VERAPAMIL IN SYSTEMIC HYPERTENSION [J].
KIOWSKI, W ;
ERNE, P ;
LINDER, L ;
BUHLER, FR .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (20) :1469-1472
[10]   PHARMACOKINETICS OF AMLODIPINE IN RENAL IMPAIRMENT [J].
LAHER, MS ;
KELLY, JG ;
DOYLE, GD ;
CARMODY, M ;
DONOHOE, JF ;
GREB, H ;
VOLZ, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S60-S63